Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study.
about
Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?Small intestinal bacterial overgrowth syndromeBetween celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivityIntestinal microbiota in functional bowel disorders: a Rome foundation reportProbiotic therapy for irritable bowel syndromeProbiotic effects on intestinal fermentation patterns in patients with irritable bowel syndromeSmall intestinal bacterial overgrowth in patients with irritable bowel syndromeUse and abuse of hydrogen breath testsUse of rifaximin in gastrointestinal and liver diseasesProfile of rifaximin and its potential in the treatment of irritable bowel syndromeAbdominal bloating: pathophysiology and treatmentUpper gastrointestinal microbiota and digestive diseasesUnraveling the ties between irritable bowel syndrome and intestinal microbiotaMethanogens, methane and gastrointestinal motilityBiomarkers of Irritable Bowel SyndromeNew insights into therapeutic strategies for gut microbiota modulation in inflammatory diseasesGut microbiota as potential orchestrators of irritable bowel syndromeA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceFrom comic relief to real understanding; how intestinal gas causes symptomsNew pathophysiological mechanisms in irritable bowel syndrome.Intestinal gas dynamics: mechanisms and clinical relevance.A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.Functional findings in irritable bowel syndrome.Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath testBreath tests and irritable bowel syndrome.Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndromeRational Use of Antibiotics in the Treatment of Functional Bowel DisordersSmall Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyGas and Bloating.Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting.Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicineThe Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome.Immune activation and gut microbes in irritable bowel syndrome.Unreliability of breath methane as a candidate indicator of functional bowel disorders.Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics eraIntestinal microbiota in pathophysiology and management of irritable bowel syndrome.Methodological issues in the study of intestinal microbiota in irritable bowel syndromeRecent advances in pharmacological treatment of irritable bowel syndrome.
P2860
Q21261900-15EBDC3E-E47B-4249-8669-474E5122F2B0Q24262889-25117322-379C-43F2-AFAB-B571B94910CDQ24623796-AD25F1F7-2070-4E0F-A60A-2740C7068760Q24631357-99C5A4EB-D032-4415-83FA-60D4BB802C7BQ24633694-1591758F-1BB5-448F-89A2-613CBAEA1589Q24655815-F1853C59-5251-443D-B290-B50AF81C971FQ24674609-671FE758-C7DC-4FC6-9C99-D1DB2610470EQ24680269-DB398C37-FFE0-47E4-B1A6-FC45296AD2EFQ26740201-FDDAA47B-5E3A-416D-862E-F1B24241B06EQ26829363-2DE0EB7E-CB24-4C26-A508-D94B1950668DQ26851622-F0085320-DB0F-4F5A-AE9E-F0A5C663B3C2Q27002380-AF9BFFB2-FF00-4E1E-AFA2-04B9CE4BEBA9Q27004645-72A957F3-3844-4DCD-AD33-DEEA9BC0EED1Q27693339-FDFC7DA1-5F74-4FE7-B9D7-0020EECAF8ECQ28069902-7D7AD097-A95C-4508-B65C-E37FAD872804Q28079638-7CCAF8CB-E824-4DB2-BFB0-FC863248FE2FQ28085584-AC609DC2-9BAD-423F-B97C-DB11B6995040Q28295210-909DCDD9-CAA6-451E-A14F-04303EECCCA1Q33430635-466FE2C8-8686-4B5A-BECC-678B622247C9Q33432064-636AA106-4716-4496-954D-7C3DFE9ECA8AQ33433539-537D9280-4862-4CBF-9529-EE61B4E6326AQ33434046-6B994C29-9277-4819-8ABF-B24E8FE9D563Q33435300-98B42B34-949D-49C1-B219-7D2DD726B81EQ33458349-8991621A-1DEE-4AB0-9BD7-7CC33A9403BFQ33462070-E4303CAB-6F16-45EF-B16C-EEFE080398F1Q33463153-91939171-E79E-4487-947A-7F2D03B9E902Q33468935-0AA6B53B-00C7-4719-B0EE-AEE9F8C10C45Q33469991-6F2708A6-7C60-4F53-A744-23B865D4C25EQ33470091-542DA96D-4506-4845-96C7-1D73231A700CQ33648535-53D129A8-A9E4-48A1-8B40-CBB9977B61A2Q33688135-A8813453-6667-47DD-B45A-FC41A295F662Q33735229-36F7231D-8FA4-4D79-95DA-722DA791AD11Q33781658-EA53CFFF-BDD1-4B86-B465-BA5AFD55F98FQ33855474-5B26AC98-0F68-47C0-B24D-73D9A2701D67Q33855849-0662AB6D-BD2D-485E-8A4E-B19EFD919916Q33916182-25B2F0BF-F05D-4801-80CB-C4A3EEC1EAE0Q33939802-DD277666-17BF-44F3-AE91-E3E2B57EE9D4Q33958729-DB141648-4BB1-4CDE-9D7E-F958F6E05EFCQ33958776-B461386C-ACFE-498D-93F8-C7273E57A594Q33958853-F1CCFEB9-1E48-44B5-B811-2D6A4C304256
P2860
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Normalization of lactulose bre ...... zed, placebo-controlled study.
@en
Normalization of lactulose bre ...... zed, placebo-controlled study.
@nl
type
label
Normalization of lactulose bre ...... zed, placebo-controlled study.
@en
Normalization of lactulose bre ...... zed, placebo-controlled study.
@nl
prefLabel
Normalization of lactulose bre ...... zed, placebo-controlled study.
@en
Normalization of lactulose bre ...... zed, placebo-controlled study.
@nl
P2860
P1476
Normalization of lactulose bre ...... zed, placebo-controlled study.
@en
P2093
Evelyn J Chow
Henry C Lin
P2860
P304
P356
10.1111/J.1572-0241.2003.07234.X
P407
P577
2003-02-01T00:00:00Z